| Citation: |
TANG Yujie, TANG Yong, HU Qing. Relationships of serum sclerostin and DKK-1 levels with severity of disease in patients with systemic lupus erythematosus[J]. Journal of Clinical Medicine in Practice, 2023, 27(15): 35-39. DOI: 10.7619/jcmp.20231208
|
To explore the relationships of serum sclerostin and Dickkopf-1 (DKK-1) levels with severity of disease in patients with systemic lupus erythematosus (SLE).
A total of 126 patients with SLE from January 2020 to January 2022 were selected as SLE group, and the patients in the SLE group were divided into mild active group (n=46), moderate active group (n=42) and severe active group (n=38) according to SLE disease activity index (SLEDAI) score; 70 healthy people in the same period were selected as control group. The serum levels of Sclerostin and DKK-1 in both groups were detected by enzyme-linked immunosorbent assay. Pearson correlation analysis was used to explore the correlations of the serum Sclerostin and DKK-1 levels with biochemical indicators in the SLE group. Multivariate Logistic regression model was used to analyze the factors affecting the severity of disease in SLE patients. Receiver operating characteristic (ROC) curve was used to assess the values of serum Sclerostin and DKK-1 in evaluating the severity of disease in SLE patients.
Serum levels of Sclerostin, DKK-1, erythrocyte sedimentation rate and anti-double stranded DNA antibody (anti-dsDNA antibody) in the SLE group were significantly higher than those in the control group, while the levels of leukocyte count, hemoglobin, lymphocyte count, platelet, complement C3 and C4 were significantly lower than those in the control group (P < 0.01). Pearson correlation analysis results showed that serum levels of Sclerostin and DKK-1 in the SLE group were significantly negatively correlated with leukocyte count, hemoglobin, lymphocyte count, platelet, complement C3 and complement C4 (P < 0.01), and were significantly positively correlated with erythrocyte sedimentation rate and anti-dsDNA antibody (P < 0.01). The serum levels of Sclerostin and DKK-1 in the severe active group were significantly higher than those in the moderate active group and mild active group, and the serum levels of Sclerostin and DKK-1 in the moderate active group were significantly higher than those in the mild active group (P < 0.05). Elevated levels of serum Sclerostin and DKK-1 were the independent risk factors affecting the severity of SLE. The area under the curve (AUC) of serum Sclerostin combined with DKK-1 for predicting high activity of SLE was 0.919 (95%CI, 0.862 to 0.956), which was significantly higher than 0.833 of serum Sclerostin (Z=4.978, 95%CI, 0.809 to 0.851, P < 0.001) and 0.841 of DKK-1 (Z=4.213, 95%CI, 0.810 to 0.867, P < 0.001).
The increased expression levels of serum Sclerostin and DKK-1 in SLE patients are related to the severity of SLE, and are the independent risk factors affecting the severity of SLE. The combination of serum Sclerostin and DKK-1 has a high predictive value for the severity of SLE.
| [1] |
BARBER M R W, DRENKARD C, FALASINNU T, et al. Global epidemiology of systemic lupus erythematosus[J]. Nat Rev Rheumatol, 2021, 17(9): 515-532. doi: 10.1038/s41584-021-00668-1
|
| [2] |
陈群, 严远飞, 陈数, 等. 系统性红斑狼疮合并心脏损害的相关危险因素分析[J]. 实用临床医药杂志, 2022, 26(1)109-115. doi: 10.7619/jcmp.20212670
|
| [3] |
TANAKA S, MATSUMOTO T. Sclerostin: from bench to bedside[J]. J Bone Miner Metab, 2021, 39(3): 332-340. doi: 10.1007/s00774-020-01176-0
|
| [4] |
GARCIA-DE LOS RÍOS C, MEDINA-CASADO M, DÍAZ-CHAMORRO A, et al. Sclerostin as a biomarker of cardiovascular risk in women with systemic lupus erythematosus[J]. Sci Rep, 2022, 12: 21621. doi: 10.1038/s41598-022-25651-y
|
| [5] |
LIU Q W, YING Y M, ZHOU J X, et al. Human amniotic mesenchymal stem cells-derived IGFBP-3, DKK-3, and DKK-1 attenuate liver fibrosis through inhibiting hepatic stellate cell activation by blocking Wnt/β-catenin signaling pathway in mice[J]. Stem Cell Res Ther, 2022, 13(1): 1-18. doi: 10.1186/s13287-021-02613-1
|
| [6] |
XUE J, YANG J L, YANG L J, et al. Dickkopf-1 is a biomarker for systemic lupus erythematosus and active lupus nephritis[J]. J Immunol Res, 2017, 2017: 1-13.
|
| [7] |
CECCARELLI F, PERRICONE C, MASSARO L, et al. Assessment of disease activity in Systemic Lupus Erythematosus: lights and shadows[J]. Autoimmun Rev, 2015, 14(7): 601-608. doi: 10.1016/j.autrev.2015.02.008
|
| [8] |
Aringer M. EULAR/ACR classification criteria for SLE[J]. Semin Arthritis Rheum, 2019, 49(3): S14-S17. doi: 10.1016/j.semarthrit.2019.09.009
|
| [9] |
YU H T, NAGAFUCHI Y, FUJIO K. Clinical and immunological biomarkers for systemic lupus erythematosus[J]. Biomolecules, 2021, 11(7): 928. doi: 10.3390/biom11070928
|
| [10] |
LU C, SHAO X, ZHOU S, et al. LINC00176 facilitates CD4+T cell adhesion in systemic lupus erythematosus via the WNT5a signaling pathway by regulating WIF1[J]. Mol Immunol, 2021, 134: 202-209. doi: 10.1016/j.molimm.2021.02.018
|
| [11] |
WANG J S, MAZUR C M, WEIN M N. Sclerostin and osteocalcin: candidate bone-produced hormones[J]. Front Endocrinol, 2021, 12: 584147. doi: 10.3389/fendo.2021.584147
|
| [12] |
PACCOU J, MENTAVERRI R, RENARD C, et al. The relationships between serum sclerostin, bone mineral density, and vascular calcification in rheumatoid arthritis[J]. J Clin Endocrinol Metab, 2014, 99(12): 4740-4748. doi: 10.1210/jc.2014-2327
|
| [13] |
HUANG X F, XIE M R, XIE Y L, et al. The roles of osteocytes in alveolar bone destruction in periodontitis[J]. J Transl Med, 2020, 18(1): 1-15. doi: 10.1186/s12967-019-02189-8
|
| [14] |
DONHAM C, MANILAY J O. The effects of sclerostin on the immune system[J]. Curr Osteoporos Rep, 2020, 18(1): 32-37. doi: 10.1007/s11914-020-00563-w
|
| [15] |
陈露, 张寅, 刘松, 等. 系统性红斑狼疮患者CD154的表达与螺旋CT冠状动脉钙化积分的关系[J]. 临床与病理杂志, 2018, 38(8): 1625-1631. https://www.cnki.com.cn/Article/CJFDTOTAL-WYSB201808006.htm
|
| [16] |
BAETTA R, BANFI C. Dkk (dickkopf) proteins[J]. Arterioscler Thromb Vasc Biol, 2019, 39(7): 1330-1342. doi: 10.1161/ATVBAHA.119.312612
|
| [17] |
TAO S S, CAO F, SAM N B, et al. Dickkopf-1 as a promising therapeutic target for autoimmune diseases[J]. Clin Immunol, 2022, 245: 109156. doi: 10.1016/j.clim.2022.109156
|
| [18] |
MICELI-RICHARD C, TAYLOR K E, NITITHAM J, et al. Genetic contribution of DKK-1 polymorphisms to RA structural severity and DKK-1 level of expression[J]. Ann Rheum Dis, 2015, 74(7): 1480-1481. doi: 10.1136/annrheumdis-2014-206530
|
| [19] |
LONG L, LIU Y Y, WANG S Y, et al. Dickkopf-1 as potential biomarker to evaluate bone erosion in systemic lupus erythematosus[J]. J Clin Immunol, 2010, 30(5): 669-675. doi: 10.1007/s10875-010-9436-z
|
| [20] |
TAN W X, QIU Y, CHEN N, et al. The intervention of intestinal Wnt/β-catenin pathway alters inflammation and disease severity of CIA[J]. Immunol Res, 2021, 69(4): 323-333. doi: 10.1007/s12026-021-09190-8
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: